How to buy Molecular Partners stock (Molecular Partners AG)

Molecular Partners is a biotechnology business based in the US. Molecular Partners shares (MOLN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $5.08 – a decrease of 6.45% over the previous week. Molecular Partners employs 167 staff and has a trailing 12-month revenue of around $6 million.

Our top picks for where to buy Molecular Partners AG ADR stock

Buy Molecular Partners stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Molecular Partners stock price (NASDAQ: MOLN)

Use our graph to track the performance of MOLN stocks over time.

Molecular Partners shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$5.08
52-week range	$3.32 - $12.70
50-day moving average more info button	$5.60
200-day moving average more info button	$5.28
Wall St. target price	$10.37
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-2.12

Is it a good time to buy Molecular Partners stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Molecular Partners price performance over time

Historical closes compared with the close of $5.22 from 2024-12-19

1 week (2024-12-13)	-3.87%
1 month (2024-11-21)	-3.69%
3 months (2024-09-20)	11.78%
6 months (2024-06-21)	-45.63%

1 year (2023-12-21)	16.52%
2 years (2022-12-21)	-20.31%
3 years (2021-12-21)	19.89
5 years (2019-12-17)	N/A

Molecular Partners financials

Revenue TTM	$6 million
Gross profit TTM	$138.9 million
Return on assets TTM	-21.17%
Return on equity TTM	-37.37%
Profit margin	0%
Book value	$4.18
Market Capitalization more info button	$199.5 million

TTM: trailing 12 months

Molecular Partners share dividends

We're not expecting Molecular Partners to pay a dividend over the next 12 months.

You may also wish to consider:

Molecular Partners share price volatility

Over the last 12 months, Molecular Partners's shares have ranged in value from as little as $3.32 up to $12.7. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Molecular Partners's is 0.537. This would suggest that Molecular Partners's shares are less volatile than average (for this exchange).

To put Molecular Partners's beta into context you can compare it against those of similar companies.

• GlycoMimetics (GLYC.US): 1.842
• Otonomy (OTIC.US): 1.5717
• Atara Biotherapeutics (ATRA.US): 0.495

Molecular Partners overview

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland. .

Frequently asked questions

What percentage of Molecular Partners is owned by institutions?
Currently 5.307% of Molecular Partners shares are held by institutions. How many people work for Molecular Partners?
Latest data suggests 167 work at Molecular Partners. When does the fiscal year end for Molecular Partners?
Molecular Partners's fiscal year ends in December. Where is Molecular Partners based?
Molecular Partners's address is: Wagistrasse 14, Schlieren, Switzerland, 8952 What is Molecular Partners's ISIN number?
Molecular Partners's international securities identification number is: US60853G1067